Live feed08:00:00·8mPRReleasevia QuantisnowScholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE TrialByQuantisnow·Wall Street's wire, on your screen.SRRK· Scholar Rock Holding CorporationHealth Care
